| Ytd | -36.86% | |
| 1y | -69.39% |
| Open | 3.00 | Prev Close | 3.10 | Low | 2.97 | High | 3.36 | Mkt Cap | 3.63M |
| Vol | 22.94K | Avg Vol | 165.74K | EPS | -3.10 | P/E | -1.04 | Forward P/E | -1.26 |
| Beta | 1.36 | Short Ratio | 0.98 | Inst. Own | 2.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 5.38 | 200-d Avg | 5.85 | 1yr Est | 10.00 |
SILO News
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Collaboration supports development of a next-generation AWS-native platform designed to accelerate c
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short in
Silo continues to add technology assets as it expands its AI business and further develops its lead
Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, ha
Silo Pharma's QwikAgents joins AMD's AI Developer Program, gaining cloud credits and tools t
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-sta
SARASOTA, FLA. , July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Compan
Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silico
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon
NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives wi
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delive
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling dev
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health i
Federal initiatives focused on PTSD and related conditions appears to validate need for new and nove
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short i
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Pro
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from
U.S. stock futures were flat on Monday after closing higher on Friday. Futures of major benchmark in
During the session on Thursday, 461 stocks hit new 52-week lows.